Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2019.5806
Abstract: Importance Targeted therapies for advanced renal cell carcinoma (RCC) have shown increased tolerability and survival advantages over older treatments in clinical trials, but understanding of real-world survival improvements is still emerging. Objective To compare overall… read more here.
Keywords: targeted therapy; group; nontargeted therapy; targeted nontargeted ... See more keywords